Blasi A, Beltran J, Pereira A, Puig L. [The cryoprecipitate: that old unknown].
ACTA ACUST UNITED AC 2015;
62:204-12. [PMID:
25561426 DOI:
10.1016/j.redar.2014.11.004]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Revised: 11/12/2014] [Accepted: 11/17/2014] [Indexed: 11/27/2022]
Abstract
Cryoprecipitate is a plasma derivative rich in fibrinogen and other procoagulant factors. It has been successfully used for decades in the treatment of the coagulopathy of trauma patients, cardiovascular surgery, liver failure and disseminated intravascular coagulation. Although cryoprecipitate is routinely used in many western countries, most of the Spanish regional blood banks stopped its production in the late 1990's. Moreover, in recent years there is a movement to replace cryoprecipitate with manufactured fibrinogen concentrate. As a consequence, many of the younger anaesthesiologists did not have any direct experience with cryoprecipitate. This article aims to describe the characteristics of cryoprecipitate since it is a different product from manufactured fibrinogen concentrate, with its own specific indications that deserve to be further studied in clinical trials.
Collapse